Petra Blahovcova

Prague, PR, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic.

Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic.

Journal: Blood advances
Published: February 04, 2026

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

Journal: Hematological oncology
Published: November 28, 2025

Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results.

Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results.

Journal: Hematological oncology
Published: July 08, 2025

Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.

Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.

Journal: British journal of haematology
Published: May 29, 2025

The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis.

The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis.

Journal: Leukemia & lymphoma
Published: March 31, 2025

Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on?

Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on?

Journal: HemaSphere
Published: March 21, 2025

R-CHOP and R-cytarabine for transplant-ineligible MCL.

R-CHOP and R-cytarabine for transplant-ineligible MCL.

Journal: Blood advances
Published: March 04, 2025

Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data.

Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data.

Journal: Annals of hematology
Published: August 02, 2024

Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.

Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.

Journal: Neoplasma
Published: October 30, 2022

Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.

Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.

Journal: Cancers
Published: June 24, 2020

Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT.

Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT.

Journal: Bone marrow transplantation
Published: January 24, 2020

Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.

Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.

Journal: American journal of hematology
Published: August 27, 2018
Showing 1-12 of 15

Last Updated: 09/26/2026